Prothena Co. PLC Stock Rating Lowered by Zacks (PRTA)
Prothena Co. PLC (NASDAQ:PRTA) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a report issued on Wednesday. They currently have a $24.20 price objective on the stock. Zacks‘s target price would indicate a potential upside of 4.72% from the company’s current price.
Prothena Co. PLC (NASDAQ:PRTA) traded down 0.82% during mid-day trading on Wednesday, hitting $22.92. 131,981 shares of the company’s stock traded hands. Prothena Co. PLC has a 1-year low of $16.71 and a 1-year high of $49.24. The stock has a 50-day moving average of $20.00 and a 200-day moving average of $26.20. The company’s market cap is $627.4 million.
Prothena Co. PLC (NASDAQ:PRTA) last released its earnings data on Monday, August 4th. The company reported $0.06 earnings per share for the quarter. The company had revenue of $15.10 million for the quarter. Analysts expect that Prothena Co. PLC will post $-0.71 EPS for the current fiscal year.
Separately, analysts at Oppenheimer initiated coverage on shares of Prothena Co. PLC in a research note on Thursday, July 10th. They set an “outperform” rating and a $40.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $37.96.
Prothena Corporation PLC is an Ireland-based, clinical-stage biotechnology company. The Company is engaged in discovering and developing monoclonal antibodies that are directed towards misfolded proteins or improper cell adhesion.
To view Zacks’ full report, visit Zacks’ official website.
Receive News & Ratings for Prothena Co PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Co PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.